Comparison of pharmacokinetic similarity, immunogenicity, and safety of mepolizumab and BAT2606 in healthy Chinese men in a double-blinded, randomized, single-dose, three-arm parallel-group phase I trial

Cuiyun Li, Jixuan Sun, Jia Xu, Min Wu, Xiaojiao Li, Zhi‐Jie Liu, Qingfeng Dong, Yu Sun, Yanhua DingFrontiers in Pharmacology 2025 · DOI

Abstract

This Phase I clinical trial evaluated the pharmacokinetic (PK) similarity, safety, and immunogenicity of BAT2606, a biosimilar candidate for mepolizumab (Nucala), in 207 healthy Chinese men. The study utilized a double-blinded, randomized, three-arm parallel-group design to compare BAT2606 against reference products sourced from the US and EU. Results confirmed that BAT2606 is pharmacokinetically equivalent to both reference products, with 90% confidence intervals for $C_{max}$ and AUC falling within the 80%–125% bioequivalence range. Furthermore, BAT2606 demonstrated a comparable safety profile and a lower incidence of anti-drug antibodies (ADAs) than the reference products.

Introduction

Severe eosinophilic asthma is a chronic inflammatory condition driven by an overproduction of eosinophils. Mepolizumab, a monoclonal antibody targeting Interleukin-5 (IL-5), is a standard-of-care treatment that significantly reduces exacerbations by inhibiting eosinophil maturation and recruitment. However, the high cost of biologics often restricts patient access. The development of biosimilars like BAT2606 aims to provide more affordable treatment options while maintaining the same standards of safety and efficacy as the original reference products.

Methodology

The trial enrolled 207 healthy Chinese men, randomized 1:1:1 to receive a single 100 mg subcutaneous injection of either BAT2606, Nucala-US, or Nucala-EU. Subjects were monitored for 113 days post-dose. The primary endpoints were PK parameters, including maximum serum concentration ($C_{max}$) and area under the curve (AUC). Secondary endpoints included the incidence of adverse events (AEs) and the development of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs).

Pharmacokinetic Equivalence

Bioequivalence was established by comparing the geometric mean ratios of PK parameters. For a biosimilar to be considered equivalent, the 90% confidence intervals for these ratios must fall between 80.00% and 125.00%.

Mean serum concentration-time curves of BAT2606, Nucala-US, and Nucala-EU on log (A) and linear (B) scales.

As illustrated above, the mean serum concentration-time profiles for BAT2606 were nearly identical to those of Nucala-US and Nucala-EU. All primary PK parameters met the predefined bioequivalence criteria. Interestingly, the researchers noted two outliers in the Nucala groups who reached $C_{max}$ significantly earlier than expected (at 2 hours), likely due to accidental injection into a small blood vessel or muscle, highlighting the sensitivity of PK monitoring in subcutaneous administration.

Safety and Immunogenicity

The safety profile of BAT2606 was consistent with the known profile of mepolizumab. Adverse events were reported in 79.1% of subjects, with the majority being mild (Grade 1 or 2). No serious adverse events, deaths, or local injection-site reactions were observed. The most common laboratory abnormality was an increase in blood triglycerides.

Immunogenicity assessments revealed that BAT2606 had a numerically lower ADA incidence (5.8%) compared to Nucala-US (14.7%) and Nucala-EU (14.5%). Crucially, no neutralizing antibodies (NAbs) were detected in any treatment group, indicating that the immune responses did not interfere with the drug's biological activity.

Conclusion

This Phase I trial successfully demonstrated the pharmacokinetic bioequivalence of BAT2606 to both US- and EU-sourced mepolizumab. With a comparable safety profile and favorable immunogenicity, BAT2606 has met the regulatory requirements to proceed to Phase III clinical trials. These results support the continued development of BAT2606 as a high-quality, accessible biosimilar for patients with severe eosinophilic asthma.

Summary updated

Abstract

https://www.clinicaltrials.gov/study/NCT05576454?term=BAT2606&rank=1.
BibTeX
@inproceedings{li2025comparison,
  author = {Cuiyun Li and Jixuan Sun and Jia Xu and Min Wu and Xiaojiao Li and Zhi‐Jie Liu and Qingfeng Dong and Yu Sun and Yanhua Ding},
  title = {{Comparison of pharmacokinetic similarity, immunogenicity, and safety of mepolizumab and BAT2606 in healthy Chinese men in a double-blinded, randomized, single-dose, three-arm parallel-group phase I trial}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2025.1580883},
}
Figure